J&J’s Bispecific Drug Wins Fast FDA Approval for Head and Neck Cancer
Article excerpt
Highlighted: the sentence this signal was extracted from
Johnson & Johnson (J&J) has received accelerated US Food and Drug Administration (FDA) approval for its bispecific antibody drug, Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), to treat adults with advanced head and neck squamous cell carcinoma (HNSCC). The approval offers a new treatment option for patients whose cancer has progressed despite standard chemotherapy and immunotherapy. This latest approval expands the drug's use beyond lung cancer, where Rybrevant was initially approved in 2021 for certain cases of non-small cell lung cancer (NSCLC). Rybrevant is a bispecific antibody that targets two receptors, epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET). Both receptors can contribute to cancer growth and treatment resistance. By blocking these two targets simultaneously, the drug aims to prevent cancer cells from developing resistance to treatment. The therapy is designed for patients who have experienced disease progression during or after currently available standard treatments. Rybrevant Faspro uses drug-delivery technology developed by Halozyme, allowing healthcare professionals to administer the treatment through a subcutaneous injection rather than an intravenous infusion. The injectable formulation takes approximately five minutes to administer, compared with two to five hours for the intravenous version. This shorter...
Keep reading with a free account
The rest of this article, and every signal for Johnson & Johnson, is in your free account.
